Genetic ablation of tumor necrosis factor‐alpha (TNF‐α) and pharmacological inhibition of TNF‐synthesis attenuates MPTP toxicity in mouse striatum

Open Access
Publisher Website
Google Scholar
Abstract
The impact of pro‐inflammatory cytokines such as tumor necrosis factor‐α (TNF‐α) in the pathology of Parkinson's disease (PD) and in MPTP neurotoxicity remains unclear. Here, male TNF‐α (–/–) deficient mice and C57bL/6 mice were treated with MPTP (4 × 15mg/kg, 24 h intervals) and in one series, thalidomide was administered to inhibit TNF‐α synthesis. Real‐time RT‐PCR revealed that the striatal mRNA levels of TNF‐α, of the astrocytic marker glial fibrillary acidic protein (GFAP) and of the marker for activated microglia, macrophage antigen complex‐1 (MAC‐1), were significantly enhanced after MPTP administration. Thalidomide (50 mg/kg, p.o.) partly protected against the MPTP‐induced dopamine (DA) depletion, and TNF‐α (–/–) mice showed a significant attenuation of striatal DA and DA metabolite loss as well as striatal tyrosine hydroxylase (TH) fiber density, but no difference in nigral TH and DA transporter immunoreactivity. TNF‐α deficient mice suffered a lower mortality (10%) compared to the high mortality (75%) seen in wild‐type mice after acute MPTP treatment (4 × 20mg/kg, 2 h interval). HPLC measurement of MPP+ levels revealed no differences in TNF‐α (–/–), wild‐type and thalidomide treated mice. This study demonstrates that TNF‐α is involved in MPTP toxicity and that inhibition of TNF‐α response may be a promising target for extending beyond symptomatic treatment and developing anti‐parkinsonian drugs for the treatment of the inflammatory processes in PD.

This publication has 76 references indexed in Scilit: